News

Endo president and CEO Rajiv De Silva said: "This strategic transaction enhances the organic growth of our branded pharmaceuticals business by adding a broad range of high quality

In order to manage the regulatory submission to the Australian Therapeutics Goods Administration (TGA) and the up-and-coming clinical trial, ISCO has established an Australian subsidiary named Cyto Therapeutics.

Imbruvica is an once-daily oral therapy that inhibits a protein called Bruton’s tyrosine kinase (BTK). It also secured breakthrough therapy designation for WM from the FDA and is

Tarextumab is a fully human monoclonal antibody that targets the Notch2 and Notch3 receptors. Currently, the company is enrolling patients in a randomized Phase II trial of tarextumab

The once-daily Evotaz is a combination of the protease inhibitor atazanavir, marketed as Reyataz (atazanavir 200mg/300mg) capsules, and cobicistat, a pharmacokinetic enhancer marketed by Gilead Sciences. According to

Facilitated by Johnson & Johnson Innovation, the deal grants Janssen an exclusive, worldwide license for an orally administered biopharmaceutical product candidate specifically designed to treat IBS. AMT uses

In the trial, a total of 111 patients were enrolled globally from sites in the US, Eastern Europe and Asia. The company said that data, secured from the

The Company has recent ly submi tted an application to the World Health Organization Pesticide Evaluation Scheme ( WHOPES ) for their recommendation on the product . SumiLarv

AgeneBio is developing AGB101, a Phase-3 ready candidate targeting a large unserved aMCI patient population. If approved, AGB101 will be the first and only therapeutic that targets hippocampus